tiprankstipranks
Trending News
More News >

SSY Group Gains Approval for Key Drug Production

Story Highlights
SSY Group Gains Approval for Key Drug Production

Confident Investing Starts Here:

SSY Group ( (HK:2005) ) has issued an announcement.

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Epinephrine Hydrochloride Injection, a critical drug for cardiopulmonary resuscitation and treatment of severe dyspnea and anaphylaxis. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing stakeholders with an updated view of its business advancements.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating essential medical products, including drugs for cardiopulmonary resuscitation and treatments for severe dyspnea and anaphylaxis.

YTD Price Performance: -4.42%

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.23B

Learn more about 2005 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1